Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis
- 16 April 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (11), 1979-1989
- https://doi.org/10.1093/cid/ciaa441
Abstract
The Infectious Diseases Society of America recommends either a fluoroquinolone or a macrolide as a first-line antibiotic treatment for Legionella pneumonia, but it is unclear which antibiotic leads to optimal clinical outcomes. We compared the effectiveness of fluoroquinolone versus macrolide monotherapy in Legionella pneumonia using a systematic review and meta-analysis. We conducted a systematic search of literature in PubMed, Cochrane, Scopus, and Web of Science from inception to 1 June 2019. Randomized controlled trials and observational studies comparing macrolide with fluoroquinolone monotherapy using clinical outcomes in patients with Legionella pneumonia were included. Twenty-one publications out of an initial 2073 unique records met the selection criteria. Following PRISMA guidelines, 2 reviewers participated in data extraction. The primary outcome was mortality. Secondary outcomes included clinical cure, time to apyrexia, length of hospital stay (LOS), and the occurrence of complications. The review and meta-analysis was registered with PROSPERO (CRD42019132901). Twenty-one publications with 3525 patients met inclusion criteria. The mean age of the population was 60.9 years and 67.2% were men. The mortality rate for patients treated with fluoroquinolones was 6.9% (104/1512) compared with 7.4% (133/1790) among those treated with macrolides. The pooled odds ratio assessing risk of mortality for patients treated with fluoroquinolones versus macrolides was 0.94 (95% confidence interval, .71–1.25, I2 = 0%, P = .661). Clinical cure, time to apyrexia, LOS, and the occurrence of complications did not differ for patients treated with fluoroquinolones versus macrolides. We found no difference in the effectiveness of fluoroquinolones versus macrolides in reducing mortality among patients with Legionella pneumonia.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (DP2AI144244)
This publication has 41 references indexed in Scilit:
- Clinical Outcomes for Hospitalized Patients with Legionella Pneumonia in the Antigenuria Era: The Influence of Levofloxacin TherapyClinical Infectious Diseases, 2005
- Antimicrobial Chemotherapy for Legionnaires Disease: Levofloxacin versus MacrolidesClinical Infectious Diseases, 2005
- Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalizationInternational Journal of Antimicrobial Agents, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Legionnaires' disease: a rational approach to therapyJournal of Antimicrobial Chemotherapy, 2003
- Adverse Drug Reactions Related to the Use of Fluoroquinolone AntimicrobialsDrug Safety, 2003
- The treatment of Legionnaires’ diseaseJournal of Antimicrobial Chemotherapy, 1999
- Antimicrobial Chemotherapy for Legionnaires' Disease: A ReviewClinical Infectious Diseases, 1995
- Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycinEuropean Respiratory Journal, 1995